14.91
-0.40 (-2.61%)
| Penutupan Terdahulu | 15.31 |
| Buka | 15.74 |
| Jumlah Dagangan | 978,234 |
| Purata Dagangan (3B) | 835,952 |
| Modal Pasaran | 880,827,008 |
| Harga / Buku (P/B) | 1.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Mar 2026 |
| EPS Cair (TTM) | -2.77 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.33% |
| Nisbah Semasa (MRQ) | 11.62 |
| Aliran Tunai Operasi (OCF TTM) | -150.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -87.13 M |
| Pulangan Atas Aset (ROA TTM) | -25.38% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.57% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Cullinan Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.55% |
| % Dimiliki oleh Institusi | 116.27% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 36.00 (Wedbush, 141.45%) | Beli |
| Median | 31.50 (111.27%) | |
| Rendah | 27.00 (HC Wainwright & Co., 81.09%) | Beli |
| Purata | 31.50 (111.27%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 12.59 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 11 Mar 2026 | 36.00 (141.45%) | Beli | 14.31 |
| Citigroup | 17 Feb 2026 | 33.00 (121.33%) | Beli | 12.19 |
| Guggenheim | 02 Feb 2026 | 30.00 (101.21%) | Beli | 12.71 |
| HC Wainwright & Co. | 08 Jan 2026 | 27.00 (81.09%) | Beli | 11.14 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 08 Jan 2026 | Pengumuman | Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |